IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
company today announced that IMV
Chief Executive Officer Frederic Ors will present at the following
investor conferences in May:
RBC Capital Markets Global Healthcare Conference
-
Date: Tuesday, May 21, 2019
-
Time: 1:35 p.m. ET
-
Location: The InterContinental New York Barclay Hotel, New
York, NY
National Bank Financials’ 9th Annual Quebec
Conference
-
Date: Wednesday, May 29, 2019
-
Time: 9:50 a.m. ET
-
Location: Museum Room, Shangri-la Hotel, Toronto, Ontario
China Bio-Partnering Forum
-
Date: Thursday, May 30, 2019
-
Time: 1:40 p.m. CT
-
Location: Renaissance Schaumburg Convention Center Hotel,
Chicago, IL
A copy of each meeting’s presentation will be available in the events
and presentations section of IMV’s website. A live webcast of IMV’s
presentation at the RBC Capital Markets conference will also be
available and archived for 90 days on the events
and presentations webpage.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious diseases. IMV
is pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology leverages a
novel mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T
cell-activating immunotherapy that combines the utility of the platform
with a target: survivin. IMV is currently assessing DPX-Survivac as a
monotherapy in advanced ovarian cancer, as well as a combination therapy
in multiple clinical studies with Merck. Connect at www.imv-inc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005899/en/
Copyright Business Wire 2019